Skin Cancer (Non-Melanoma) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 29 studies associated with Skin Cancer (Non-Melanoma).
Here is a small sampling of Skin Cancer (Non-Melanoma) studies by title:
- Eucalyptol targets PI3K/Akt/mTOR Pathway to inhibit Skin Cancer Metastasis
- Topical cannabidiol (CBD) in skin pathology – A comprehensive review and prospects for new therapeutic opportunities
- Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology
- Biological effects of cannabidiol on human cancer cells: Systematic review of the literature
- Geraniol exerts its antiproliferative action by modulating molecular targets in lung and skin carcinoma cells
Components of the Skin Cancer (Non-Melanoma) Research Dashboard
- Dosing information available for Skin Cancer (Non-Melanoma)
- Chemotype guidance for treating Skin Cancer (Non-Melanoma) with cannabis
- Synopsis of cannabis research for Skin Cancer (Non-Melanoma)
- Individual study details for Skin Cancer (Non-Melanoma)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Skin Cancer (Non-Melanoma)
Description of Skin Cancer (Non-Melanoma)
Non-melanoma skin cancers are one of the most common cancers diagnosed to date. With a relatively easy diagnosis and treatment, most non-melanoma skin cancer treatments result in a positive outcome. Allopathic treatment includes forms of surgical removal using type- appropriate tools to shave off the cancerous tissue. The actual slicing may involve using a topical electrical current to stop bleeding and, ideally, to zap the remaining cancer cells. Surgeons may use lasers to vaporize tissue, a wire brush to sand off skin, or freeze the affected tissue (cryosurgery). Depending on the breadth and depth of the cancer, physicians may also use chemotherapies or radiation.
Non-melanoma Skin Cancer
ICD-10 Code: C44
Skin Cancer (Non-Melanoma) Symptoms:
Raised area (lump), skin sores that won't heal (crust, crack, bleed), reddish/white in color, may have waxy appearance, slowly growing
Also known as:
Basal Cell Carcinoma, Nonmelanoma malignant neoplasm
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.